Financial Survey: Amplifon (OTCMKTS:AMFPF) versus Amarantus Bioscience (OTCMKTS:AMBS)

Amplifon (OTCMKTS:AMFPF) and Amarantus Bioscience (OTCMKTS:AMBS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Amplifon and Amarantus Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amplifon	0	1	1	0	2.50
Amarantus Bioscience	0	0	0	0	0.00

Given Amarantus Bioscience’s higher probable upside, analysts plainly believe Amarantus Bioscience is more favorable than Amplifon.

Profitability

This table compares Amplifon and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amplifon	5.20%	13.49%	3.88%
Amarantus Bioscience	N/A	N/A	N/A

Risk & Volatility

Amplifon has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amplifon and Amarantus Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amplifon	$2.61 billion	1.51	$157.31 million	$0.61	28.62
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

Amplifon has higher revenue and earnings than Amarantus Bioscience.

Summary

Amplifon beats Amarantus Bioscience on 6 of the 8 factors compared between the two stocks.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.